Douglas Lane & Associates LLC increased its stake in Stanley Black & Decker (SWK) by 47.4%, acquiring an additional 34,365 shares to hold a total of 106,850 shares valued at approximately $7.94 million. Analysts currently have a "Hold" rating on the stock with an average price target of $85.56. Despite beating EPS estimates in its latest quarterly results, Stanley Black & Decker missed slightly on revenue and has a high dividend payout ratio of 125%, raising concerns about sustainability.

Douglas Lane & Associates LLC significantly reduced its stake in Ford Motor Company by 80.7% in Q4 2025, selling over 1.6 million shares and retaining 386,231 shares valued at approximately $5.07 million. Despite Ford beating Q4 earnings estimates with $0.13 EPS on $45.89 billion in revenue, its revenue was down 4.8% year-over-year. The article also notes insider buying by William Clay Ford Jr. and reiterates a consensus "Hold" rating from analysts with an average price target of $13.66.

Capital Investment Advisory Services LLC significantly reduced its stake in Uber Technologies (NYSE:UBER) by 80.8% in Q4, selling off 47,913 shares. Despite this institutional selling and mixed insider activity, analysts maintain a "Moderate Buy" rating with a consensus price target of $105.14 for Uber. The company's Q4 adjusted EPS missed estimates, while revenue surpassed expectations, and it continues to pursue new revenue streams through business expansion and AI investments.

Fiduciary Alliance LLC significantly increased its stake in Hormel Foods Corporation, purchasing an additional 76,032 shares in Q4, bringing its total holdings to 118,325 shares valued at $2.80 million. Hormel Foods recently declared a quarterly dividend of $0.2925, resulting in an annualized yield of 5.6%, and the company's Q1 EPS of $0.34 surpassed analyst estimates. Analysts currently rate Hormel Foods with a consensus "Hold" and an average price target of $27.00.

Fiduciary Alliance LLC recently acquired 98,343 shares of Weyerhaeuser Company ($WY) valued at $2.33 million during the fourth quarter, contributing to institutional investors owning nearly 83% of the company. Despite insider selling, directors Richard Beckwitt and James Calvin O'rourke made significant share purchases. Weyerhaeuser reported beating Q4 EPS estimates and offers a quarterly dividend of $0.21, with analysts giving it a consensus "Hold" rating and an average price target of $28.88.

Cliftonlarsonallen Wealth Advisors LLC has increased its stake in Walmart Inc. (NASDAQ:WMT) by 42.7%, acquiring an additional 10,074 shares and bringing its total holding to 33,693 shares, valued at approximately $3.75 million. This coincides with Walmart's strong Q4 earnings, where it beat revenue and EPS estimates and provided optimistic FY2027 guidance. Despite institutional buying, Walmart insiders have been selling shares, with executives disposing of over $33.8 million in stock within the last 90 days.

Snap has announced a multi-year partnership with Qualcomm, leveraging Snapdragon XR platforms for future generations of its Specs AR glasses, which are slated for a consumer launch in late 2026. This collaboration builds on an existing relationship and is a strategic move to position Specs as a standalone AR platform, focusing on on-device AI, graphics, and multi-user digital experiences. The establishment of Specs Inc. as a distinct subsidiary earlier in the year underscores Snap's commitment to the project's public launch.

SOPHiA GENETICS (NASDAQ:SOPH) President Ross Muken sold 2,786 shares totaling $13,484.24 on April 8th, as part of a Rule 10b5-1 trading plan to cover tax withholding on vested awards. This sale, alongside other recent dispositions, reduced his stake by 0.40%. The company's stock is trading at $4.70, with a market cap of $321.90 million, and recently reported an EPS miss; analysts currently rate SOPHiA GENETICS as "Hold" with a $7.00 price target.

This page provides a comprehensive resource for Healthpeak Properties (DOC) SEC filings, including annual 10-K, quarterly 10-Q, and material event 8-K reports, along with insider trading forms. It highlights recent filings such as a federal tax disclosure update and CEO stock purchases, offering AI-powered summaries and real-time updates for investors,

Wall Street Zen has downgraded Prime Medicine (NASDAQ:PRME) from a "sell" to a "strong sell" rating. Despite this, other analysts offer a "Moderate Buy" consensus with a target price of $7.38, while the stock currently trades around $3.43. The company, focused on gene editing technologies, has seen significant institutional investor activity in the last quarter.